Bacterial resistance to antimicrobial agents;Resistencia bacteriana en Chile

Revista Chilena de Infectologia

Volumn 20, Issue SUPPL. 1, 2003, Pages

  García C, Patricia ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Bacterial resistance; Community acquired infections; Nosocomial infections; Surveillance

Indexed keywords

EID: 33749006705     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. File T M. Overview of resistance in the 1990s. Chest 1999; 115: S3-8.
2. Trucco O, Prado V, Duran C y Grupo PRONARES. Red de vigilancia de resistencia antimicrobiana PRONARES. Informe primer semestre 2001. Rev Chil Infect 2002; 19: S140-8.
3. Sader H, Jones R N, Andrade-Baiocchi S, Biedenbach D J and the SENTRY participant group (Latin América). Four-year evaluation of frecuency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diag Microbiol Infect Dis 2003; 44: 273-80.
4. Thornsberry C. Antimicrobial Resistance: Yesterday, today and tomorrow. 103 General Meeting American Society for Microbiology. Washington DC. May 2003.
5. Gales A C, Jones R N, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns and molecular typing in the Global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Inf Dis 2001; 32: S146-55.
6. Carmeli Y, Troillet N, Karchmer A W, Samore H M. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159: 1127-32.
7. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically ; Approved Standard- Sixth Edition. M7A6, Vol 23 (2): 12.
8. Grist R. External factors affecting imipenem performance in dried microdilution MIC plates. J Clin Microbiol 1992, 30: 535-6.
9. O'Rourke E J, Lambert K G, Parsonnet K C, Macone A B, Goldmann D A. False resistance to imipenem with a microdilution susceptibility testing system. J Clin Microbiol 1991; 29: 827-9.
10. 10.- White R L, Kays M B, Friedrich L V, Brown E W, Koonce J R. Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels. J Clin Microbiol 1991; 29: 398-400.
11. 11.- Carmell Y, Eichelberger K, Soja D et al. Failure of quality control measures to prevent reporting of false resistance to imipenem in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa. J Clin Microbiol 1998; 36: 595-7.
12. 12.- Joyanes P, del Carmen Conejo M, Martínez-Martínez, L, Perea E J. Evaluation of the VITEK 2 System for the identification and susceptibility testing of three species of nonfermenting Gram-negative rods frequently isolated from clinical samples. J Clin Microbiol 2001; 39: 3247-53.
13. 13.- Steward C D, Mohammed J M, Swenson J M et al. Antimicrobial susceptibility testing of Carbapenems: Multicenter validity testing and accuracy levels of five antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates. J Clin Microbiol 2003; 41: 351-8.
14. 14.- Tennover F, Hindler J. CDC, Division of healthcare quality promotion, issue in healthcare settings. Laboratory detection of imipenem or meropenem resistance in Gram-negative organisms. http:// www.cdc.gov/ncidod/hip/ Lab/FactSheet/imipenem.htlm
15. st Century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microb Rev 2001; 14: 933-51.
16. 16.- Lautenbach E, Patel J B, Bilker W B, Edelstein P H, Fishman N O. Extended-Spectrum b-Lactamase producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-71.
17. 17.- Jacoby G A, Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 1996; 34: 908-11.
18. 18.- Porte L, García P, Sánchez T, Varela C, Labarca J, Zamorano J. Estrategia de bajo costo para la confirmation fenotípica de β-lactamasas de espectro expandido. XIX Congreso Chileno de Infectología. 2001
19. 19.- Cormican M G, Marshall S A, Jones R N. Detection of extended-spectrum β-lactamases-producing strains by the Etest ESBL screen. J Clin Microbiol 1996; 34: 1880-4.
20. 20.- Sanders C C, Barry A L, Washington J A et al. Detection of extended-spectrum β-lactamases-producing members of the Family Enterobacteriaceae with the Vitek ESBL Test. J Clin Microbiol 1996; 34: 2997-3001.
21. 21.- Tenover F C, Mohamed M J, Stelling J, O'Brien T, Williams R. Ability of laboratories to detect emerging antimicrobial resistance: Proficiency testing and quality control results from the World Health Organization's External Quality Assurance System for antimicrobial susceptibility testing. J Clin Microbiol 2001; 39: 241-50.
22. 22.- Sánchez T, García P, Riedel I, Guzmán A M. Evaluación de un sistema comercial para la detección de β-lactamasas de espectro expandido en cepas de E. coli y K. pneumoniae. XIX Congreso Chileno de Infectología. 2001.
23. 23.- Zemelman R, Valenzuela L, Domínguez M, Bello H, González G, Zemelman C. Detección de β-lactamasas de espectro extendido en el laboratorio de microbiología. Rev Chil Infect 2002; 19 (Supl): S92-5.
24. 24.- Mella S, Zemelman C, Bello H, Domínguez M, Gonzalez G, Zemelman R. Propiedades microbiológicas, clasificación y relación estructura-actividad de cefalosporinas e importancia de las cefalosporinas de cuarta generación. Rev Chil Infect 2001; 18: 7-19.
25. 25.- Valenzuela M T, Prat S, Santolaya M E et al. Implementación de una Red Nacional para la Vigilancia de Resistencia de agentes patógenos a antimicrobianos según síndromes clínicos. Rev Chil Infect 2003; 20: 119-25.
26. 26.- Santolaya ME. Implementación de una Red Nacional para la Vigilancia de Resistencia de agentes patógenos a antimicrobianos según síndromes clínicos. Editorial. Rev Chil Infect 2003; 20: 87-8.